Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Income (2020 - 2023)

Cullinan Therapeutics has reported Net Income over the past 4 years, most recently at -$25.6 million for Q4 2023.

  • Quarterly results put Net Income at -$25.6 million for Q4 2023, up 5.63% from a year ago — trailing twelve months through Dec 2023 was -$155.1 million (down 242.04% YoY), and the annual figure for FY2025 was -$219.9 million, down 31.21%.
  • Net Income for Q4 2023 was -$25.6 million at Cullinan Therapeutics, up from -$39.2 million in the prior quarter.
  • Over the last five years, Net Income for CGEM hit a ceiling of $174.1 million in Q2 2022 and a floor of -$58.1 million in Q1 2023.
  • Median Net Income over the past 4 years was -$21.6 million (2021), compared with a mean of -$10.8 million.
  • Peak annual rise in Net Income hit 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
  • Cullinan Therapeutics' Net Income stood at -$29.1 million in 2020, then fell by 17.57% to -$34.2 million in 2021, then grew by 20.81% to -$27.1 million in 2022, then increased by 5.63% to -$25.6 million in 2023.
  • The last three reported values for Net Income were -$25.6 million (Q4 2023), -$39.2 million (Q3 2023), and -$32.2 million (Q2 2023) per Business Quant data.